Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 3Phase 2 2

Status

Completed 24Terminated 13Unknown 8Recruiting 6Active not recruiting 5Withdrawn 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Genitourinary 1

Conditions

Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Decitabine × Clear all
NCT05740449 2024-06-21

HEM-iSMART A

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04493099 2020-11-12

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡